KLOW

KLOW is not a peptide. It is a vendor blend name for several separate peptides freeze-dried into one vial, and the usual 80 mg version contains four of them: 50 mg of GHK-Cu, a copper complex of the three-amino-acid peptide glycyl-histidyl-lysine; 10 mg of BPC-157, a fifteen-amino-acid sequence taken from a protein in human stomach juice and named body protection compound; 10 mg of TB-500, a synthetic piece of thymosin beta-4, a peptide your own platelets and white blood cells release into a wound; and 10 mg of KPV, a three-amino-acid tail fragment of alpha-melanocyte-stimulating hormone, written as alpha-MSH. The name comes from an older three-peptide blend sold as GLOW, with the K of KPV added. The cheatsheet description above lists only three components, which is how some vendors label it, so read the label on the vial you actually have. A PubMed search for KLOW as a peptide blend returns zero records, and each of the four components has its own page on this site; GHK-Cu in particular is covered in depth there and is only summarised here.

• Skin appearance and post-procedure recovery, which is the GHK-Cu half of the pitch and the only component with randomised human trials, both of them topical
• Tendon, ligament and muscle repair, which is what the BPC-157 and TB-500 rat studies model
• Gut inflammation, the setting where both BPC-157 and KPV have their strongest animal data
• General anti-inflammatory use, the reason KPV is added to the older GLOW formula
• Hair density, a claim that rests on GHK-Cu and on a single uncontrolled scalp study of a six-ingredient injection

Think of a repair job that needs four different trades. GHK-Cu is the supplier delivering copper, the material the crew needs to strip out old collagen and lay down new. BPC-157 behaves like the roadworks team opening blood supply to the site, while TB-500 frees up the internal scaffolding that cells use to crawl into a gap. KPV is the site manager telling the inflammatory crowd to quieten down. Putting four trades in one van is convenient, but nobody has published a job where all four turned up together, so the combined result is assumed rather than measured.

1. Before day 1There is no published human timeline for this blend, because there is no published human study of it. Everything below is drawn from studies of the individual components, none of which used this mixture, these amounts or this route.
2. Week 1-2Nothing in the literature describes what the blend does in a first fortnight. The rat tendon studies dose daily from the day after surgery, and the KPV colitis models measure body-weight recovery over roughly this window in mice.
3. Week 4Four weeks was the endpoint of the 2026 rat Achilles study that tested BPC-157 and TB-500 separately and together. TB-500 alone reached a significant biomechanical advantage; the combination did not add anything over single-agent treatment.
4. Week 8-12Twelve weeks was the endpoint of the 2006 randomised trial of topical GHK-Cu after carbon dioxide laser resurfacing, where blinded evaluators and computer analysis found no difference from the control regimen on wrinkles or skin quality.
5. Month 3+No study of any duration has followed people taking these four peptides together, so long-run effects, copper status and immune responses are all unrecorded.

• No adverse events have been reported for the blend itself in any published study, because no published study of the blend exists; that is an absence of data, not an absence of risk
• In the component trials that did report safety, the 2015 thymosin beta-4 eye-drop trial recorded no adverse events in either arm, and the 2006 topical GHK-Cu laser trial reported no treatment-related problems attributable to the peptide arm
• The United States Food and Drug Administration states that compounded drugs containing BPC-157, thymosin beta-4 and injectable GHK-Cu may pose a risk for immunogenicity because of the potential for aggregation and peptide-related impurities, and that it has identified no or only limited human exposure data for these substances and for KPV
• A 2026 review in Sports Medicine covering unapproved peptide therapies concluded that rigorous human safety data are scarce and that there is potential for serious harm to patients
• Injecting four peptides at once means that if something does go wrong you have no way of knowing which one caused it, and no way of stopping just that one
• Copper is the specific unknown here, since GHK-Cu is by mass the bulk of the vial and no published study has tracked serum copper, ceruloplasmin or zinc during repeated injected use

• You are pregnant, trying to conceive, or breastfeeding, as no reproductive safety data exist for any of the four components by injection
• You have a current or past cancer diagnosis, since GHK-Cu, BPC-157 and TB-500 are all described in the literature as pro-angiogenic or as promoters of cell proliferation
• You have Wilson disease or any other disorder of copper handling, or you take a copper chelator such as penicillamine or trientine, because the largest component of the vial exists to deliver copper
• You compete in a tested sport, since BPC-157 is named under class S0 of the World Anti-Doping Agency Prohibited List and thymosin beta-4 and its derivatives including TB-500 are named under class S2
• You have an active inflammatory bowel condition or an autoimmune diagnosis and no specialist is supervising you, since KPV and BPC-157 are being used here to alter immune signalling
• You are not working with a physician who knows exactly what is in your vial and can check your bloodwork, including copper and zinc

• Reading component research as evidence for the blend. Every study cited on this page tested one peptide, or at most two, in isolation, and the one study that tested a combination found it added nothing over the better single agent
• Not checking the ratio on your own label. On the common 50/10/10/10 split, the 2 mg cheatsheet dose is about 1.25 mg of GHK-Cu and only 0.25 mg each of BPC-157, TB-500 and KPV, which is well below the amounts usually run when those peptides are dosed on their own
• Assuming a fixed blend can be titrated. You cannot raise one component without raising all four, so if the copper load is what concerns you there is no dose that fixes it
• Treating the blue colour as a quality check. The colour is the copper in GHK-Cu and tells you nothing about how much of any peptide is present, or whether four peptides freeze-dried together stay stable in one vial, which nobody has published
• Storing it carelessly. Keep the lyophilised vial cold and dark, reconstitute with bacteriostatic water, refrigerate afterwards and protect it from light; GHK-Cu is reported in the formulation literature to be awkward to keep stable in solution
• Running it alongside a separate GHK-Cu, BPC-157 or TB-500 vial and double-dosing a component without noticing